New Insight into the Clinical Pharmacokinetics of Cefaclor: Tissue Penetration

REFERENCES

• Periti P. II cefacloro, farmaco antimicrobico modello nella valutazione farmacologica clinica delle betalattamine cefemiche orali. Farm Ter 1994; XI ( Suppl al n 1): 5-43.
   Google Scholar
• Periti P, Mazzei T, Mini E, Novelli A. Ii Cefacloro Ritardo, antibiotico a ponte fra le cefalosporine orali di 2 e generazione. Farm Ter 1994; XI (3-4): 103-125.
   Google Scholar
• Periti P. Rationale choice of an oral beta-lactam antibiotic. J Chemother 1997; 9 (Suppl 4): 1–23.
   PubMedGoogle Scholar
• Brumfitt W, Hamilton-Miller JMT. Cefaclor into the Millenium - Review. J Chemother 1999; 11 (3): 163–178.
   PubMed Web of Science ®Google Scholar
• Derry JE. Evaluation of cefaclor. Am J Host Pharm 1981; 38: 54–58.
   PubMedGoogle Scholar
• Sides GD, Franson TR, De Sante KA, Black HR. A comprehensive review of the clinical pharmacology and phar-macokinetics of cefaclor. Clin Ther 1988; 11 ( Suppl A): 5-17.
   Google Scholar
• Tsuji A, Terasaki T, Tamai I, Hirooka H. H± gradient-dependent and carrier-mediated transport of cefixime, a new cephalosporin antibiotic, across brush border membrane vesicles from rat small intestine. J Pharmacol Expt Ther 1987; 241 (2): 594–601.
   PubMed Web of Science ®Google Scholar
• Dantzing AH, Bergin L. Uptake of the cephalosporin, cephalexin, by a dipeptide transport carrier in the human intestinal cell line, Caco-2. Biochin Biophys Acta 1990; 1027: 211–217.
   PubMed Web of Science ®Google Scholar
• Dantzing AH, Duckworth DC, Tabas LB. Transport mechanisms responsible for the absorption of loracarbed, cefixime, and cefuroxime axetil into human intestinal Caco-2 cells. Biochim Biophys Acta 1994; 1191: 7–13.
   PubMed Web of Science ®Google Scholar
• Hillgren KM, Kato A, Borchardt RT. In vitro systems for studying intestinal drug absorption. Med Res Rev 1995; 15 (2): 83–109.
   PubMed Web of Science ®Google Scholar
• Dantzing AH, Tabas LB, Bergin L. Cefaclor uptake by the proton-dependent dipeptide transport carrier of human intestinal Caco-2 cells and comparison to cephalexin uptake. Biochim Biophys Acta 1992; 1112: 167-173.
   Google Scholar
• Hodges GR, Liu C, Hinthorn DR, et al. Pharmacological evaluation of cefaclor in volunteers. Antimicrob Agents Chemother 1978; 14: 454–456.
   PubMed Web of Science ®Google Scholar
• Korzeniowski OM, Scheld M, Sande MA. Comparative pharmacology of cefaclor and cephalexin. Antimicrob Agents Chemother 1977; 12: 157–162.
   PubMed Web of Science ®Google Scholar
• Meyers BR, Hirschman SZ, Wormser G, et al. Pharmacologic studies with cefaclor, a new oral cephalosporin. J Clin Pharmacol 1978; 19: 174–179.
   Google Scholar
• Glynne A, Goulbourn RA, Ryden R. A human pharma-cology study of cefaclor. J Antimicrob Chemother 1978; 4: 343–348.
   PubMed Web of Science ®Google Scholar
• Cockburn J, Reid AL, Bowman JA, Sanson-Fisher RW. Effects of intervention on antibiotic compliance in general practice. Med J Australia 1987; 147: 324–328.
   PubMed Web of Science ®Google Scholar
• Satterwhite JH, Cerimele BJ, Coleman DL, Hatcher BL, Kisicki J, De Sante KA. Pharmacokinetics of cefaclor AF: effects of age, antiacids and H2-receptor antagonist. Postgrad Med J 1992; 68 (Suppl 3): S3–S9.
   PubMedGoogle Scholar
• Brumfitt W. Introductory remarks. Postgrad Med J 1992; 68 (Suppl 3): S1–S2.
   PubMed Web of Science ®Google Scholar
• Finegold SM, Ingram-Drake L, Gee R, et al. Bowel flora changes in humans receiving cefixime (CL 284,635) or cefa-clor. Antimicrob Agents Chemother 1987; 31 (3): 443–446.
   PubMed Web of Science ®Google Scholar
• Nord CE, Heimdahl A, Lundberg C, Marklund G. Impact of cefaclor on the normal human oropharyngeal and intestinal microflora. Scand J Infect Dis 1987; 19: 681–685.
   PubMed Web of Science ®Google Scholar
• Gillet AP, Andrews JM. Comparative in vitro microbio-logical activity and stability of cefaclor. Postgrad Med J 1979; 55 (Suppl 4): 9–11.
   Google Scholar
• Krammer RB. Panel discussion at a symposium held at the Royal College of Physicians. London, September 1978. Postgrad Med J 1979; 55 (Suppl 4): 32-34.
   Google Scholar
• Preston DA. Panel discussion at a symposium held at the Royal College of Physicians. London, September 1978. Postgrad Med J 1979; 55 (Suppl 4): 32-34.
   Google Scholar
• Blok R, Szwed JJ, Sloan RS. Pharmacokinetics of cefa-clor in normal subjects and patients with chronic renal failure. Antimicrob Agents Chemother 1977; 12: 730–732.
   PubMed Web of Science ®Google Scholar
• Simon C, Gatzemeirer U. Serum and sputum levels of cefaclor. Postgrad Med J 1979; 55 (Suppl 4): 30–34.
   PubMedGoogle Scholar
• Peterson LR, Zinneman HH, Gerding DN. Standardization of a preoperative ultracentrifuge method for quantitative determination of protein binding of seven antibi-otics. J Infect Dis 1977; 136: 778–783.
   PubMed Web of Science ®Google Scholar
• Periti P, Mazzei T, Mini E, Novelli A. Attualita delle cefalosporine in chemioterapia. E.R.S. Srl, Firenze 1988.
   Google Scholar
• Berman SJ, Boughton WH, Sugihara JG, Wong EGC, Sato MM, Siemsen AW. Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis. Antimicrob Agents Chemother 1978; 14: 281–283.
   PubMed Web of Science ®Google Scholar
• Muller O, Ruckert U, Fabricius K. Untersuchungen zur Exkretion von Cefaclor in menschlicher Galle. Infectio 1979; 7 (Suppl 6): S642–S627.
   Google Scholar
• Preston DA. Global surveillance of bacterial susceptibili-ty to cefaclor: 1988-1990. Clin Therap 1993; 15: 88–96.
   PubMed Web of Science ®Google Scholar
• Frimodt-Moller N, Bentzon MW, Thomsen WF. Experimental infection with Streptococcus pneumoniae in mice: correlation of in vitro activity and pharmacokinetic parameters with in vivo effect for 14 cephalosporins. J Infect Dis 1986; 154: 511–517.
   PubMed Web of Science ®Google Scholar
• O'Callagan CH, Kirby SM. Some cephalosporins in clinical use and their structure-activity relationships. Postgrad Med J 1970; 46 (suppl): 9-13.
   Google Scholar
• Lorian V, Atkinson B. Bactericidal effect of polymor-phonuclear neutrophils on antibiotic-induced filaments of Gram-negative bacilli. J Infect Dis 1984; 149: 719–727.
   PubMed Web of Science ®Google Scholar
• Novelli A. Molecular factors responsible for the clinical efficacy of cefaclor. In: Current Issues in the Management of Respiratory Tract Infections: a Focus on Cefaclor (Cole P, Ed), Round Table series no. 53. Royal Society of Medicine Press Ltd, London 1998: 25-35.
   Google Scholar
• Grant M, Raeburn JA, Sutherland R, Harkness RA, Gormley IP, Kowolik MJ. Effect of two antibiotics on human granulocyte activities. J Antimicrob Chemother 1983; 11: 543–554.
   PubMed Web of Science ®Google Scholar
• Periti P. Immunopharmacology of oral betalactams. J Chemother 1998; 10 (2): 91–96.
   PubMed Web of Science ®Google Scholar
• National Committee for Clinical Laboratory Standards. Performance standard for antimicrobial susceptibility testing: 8th informational supplement. Document M100-58. NCCLS, Wayne PA, 1998.
   Google Scholar
• Van Klingeren B, Mouton RP. Standaardisatievan-gevoeligheids-bepalingen. Rijksinstituut voor Volksgezondheid, Bilthoven, 1990.
   Google Scholar
• Report. Comité de l'Antibiogramme de la Societe Francaise de Microbiologie. Clin Microbiol Infect 1996; 2 (Suppl 1): S1–S49.
   Google Scholar
• Olsson-Liljequist B, Larsson P, Walder M, Miorner H. Antimicrobial susceptibility testing in Sweden. III. Methodology for susceptibility testing. Scand J Infect Dis 1997; Suppl 105: 13-23.
   Google Scholar
• Wise R. The pharmacokinetics of the oral cephalosporins - a review. J Antimicrob Chemother 1990; 26 ( Suppl E): 13-20.
   Google Scholar
• Eden T, Anari M, Ernstson S, Sundberg L. Penetration of cefaclor to adenoid tissue and middle ear fluid in secretory otitis media. Scand J Infect Dis Suppl 1983; 39: 48–52.
   PubMedGoogle Scholar
• Krause PJ, Owens NJ, Nightingale CH, Klimek JJ, Lehmann WB, Quintiliani R. Penetration of amoxicillin, cefa-clor, erythromycin-sulfisoxazole and trimethoprim-sulfamethox-azole into the middle ear fluid of patients with chronic serous otitis media. J Infect Dis 1982; 145: 815–821.
   PubMed Web of Science ®Google Scholar
• Ernstson S, Anari M, Eden T, Sundberg L. Penetration of cefaclor to adenoid tissue and middle ear effusion in chron-ic OME. Act Otolaryngol 1985; Suppl 424: 7-12.
   Google Scholar
• Bizet C, Pangon B, Moisy N, Bizet J, Sure A, Gehanno P. Etude comparee de la penetration de la penicilline V, de l'amoxicilline, du cefaclor et de la josamycine dans les amyg-dales. Path Biol 1989; 37: 273–275.
   PubMedGoogle Scholar
• Baldwin DR, Honeybourne D, Wise R. Pulmonary dis-position of antimicrobial agents: in vivo observations and clin-ical relevance. Antimicrob Agents Chemother 1992; 36: 1176–1180.
   PubMed Web of Science ®Google Scholar
• Marlin GE, Nicolls AJ, Funnell GR, Bradbury R. Penetration of cefaclor into bronchial mucosa. Thorax 1984; 39: 813–817.
   PubMed Web of Science ®Google Scholar
• Baldwin DR, Maxwell SRJ, Honeyburne D, Andrews JM, Ashby JP, Wise R. The penetration of cefpirome into the potential sites of pulmonary infection. J Antimicrob Chemother 1991; 28 (1): 79–86.
   PubMed Web of Science ®Google Scholar
• Nix DE, Goodwin SD, Peloquin CA, Rotella DL, Schentag JJ. Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning. Antimicrob Agents Chemother 1991; 35: 1947–1952.
   PubMed Web of Science ®Google Scholar
• Novelli A, Ciuffi M, Reali UM, Mazzei T, Periti P. The suction blister technique as a tool in antimicrobial drug phar-macokinetics. Drug Exptl Clin Res 1983; 9: 555–559.
   Google Scholar
• Mazzei T, Periti P. Tissue penetration of antimicrobial drugs. In: Pharmacokinetics and antibiotics efficacy (Genazzani E, Ed). Proceedings of an international workshop. Masson Italia, Milano 1986: 91-103.
   Google Scholar
• Gibaldi M, Perrier D. Pharmacokinetics, 2nd ed. Marcel Dekker, New York, 1982.
   Google Scholar
• Gomeni R. PHARM—an interactive graphic program for individual and population pharmacokinetic parameter esti-mation. Comput Biol Med 1984; 14 (1): 25–34.
   PubMed Web of Science ®Google Scholar
• Baldwin DR. The penetration of novel intravenous cephalosporins into the lung. J Chemother 1996; 8 (Suppl 2): 71–82.
   PubMedGoogle Scholar
• Wilding IR. Evolution of the biopharmaceutics classifica-tion system (BCS) to oral modified release (MR) formulations; what do we need to consider? - Commentary. Eur J PharmSci 1999; 8: 157–159.
   PubMed Web of Science ®Google Scholar
• Amidon GL, Lennernas H, Shoh VP, Crison JR. A the-oretical basis for a biopharmaceutic drug classification; the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12: 413–420.
   PubMed Web of Science ®Google Scholar
• Davis SS, Hardy JG, Fara JW. The intestinal transit of pharmaceutical dosage forms. Gut 1986; 27: 886–892.
   PubMed Web of Science ®Google Scholar
• Ishibashi T, Pitcairn GR, Yoshino H, Mizobe M, Wilding IR. Scintigraphic evaluation of a new capsule-type colon specific drug delivery system in healthy volunteers. J Pharm Sci 1998; 87: 531–535.
   PubMed Web of Science ®Google Scholar
• Rubas W, Cromwell MEM, Shahrokh Z, et al. Are Caco-2 cells predictive of transport and/or metabolic proper-ties of mammalian intestinal tissues? Eur J Pharm Sci 1997; 5 (Suppl 2): S13–S4.
   Google Scholar
• Wise R. Methods for evaluating the penetration of I3-lac-tam antibiotics into tissues. Rev Infect Dis 1986; 8 (Suppl 3): S325–S332.
   PubMedGoogle Scholar
• Cars O. Pharmacokinetics of antibiotics in tissues and tissue fluids: a review. Scand J Infect Dis 1991; Suppl 74: 23-33.
   Google Scholar
• Wise R. Tissue penetration of the fourth generation parenteral cephalosporins. J Chemother 1996; 8 (Suppl 2): 63–72
   PubMedGoogle Scholar
• Drusano GL, Craig WA. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respi-ratory tract infections. J Chemother 1997; 9 (Suppl 3): 38–44.
   PubMed Web of Science ®Google Scholar
• Levison ME, Santoro J, Agarwal BN. In vitro activity and pharmacokinetics of cefaclor in normal volunteers and patients with renal failure. Postgrad Med J 1979; 55 (S4): 12–16.
   PubMedGoogle Scholar
• Andrews JM, Wise R, Baldwin DR, Honeybourne D. Concentrations of ceftibuten in plasma and the respiratory tract following a single 400 mg dose. Int J Antimicrob Agents 1995; 5: 141–144.
   PubMed Web of Science ®Google Scholar